Oral Presentation Clinical Oncology Society of Australia Annual Scientific Meeting 2017

Current clinical trials investigating integration of immune therapy and radiotherapy: Focus on ablative radiotherapy combinations (#5)

Shankar Siva 1
  1. Peter MacCallum Cancer Centre, Melbourne East, VIC, Australia

Radiotherapy has long been known to have immune modulating properties. However, radiation alone is usually insufficient to cause rejection of metastatic tumour deposits distant to that of the irradiated target (the 'abscopal effect'). In the current era of clinically efficacious immunotherapeutic agents, there is renewed interest in investigation of combinations with radiation. In this presentation we explore the biological basis of combining radiation with immunotherapy, and subsequently give an overview of clinical trials currently available in the region for these combinations. In particular, there will be a focus on stereotactic ablative body radiotherapy (SABR) combinations with checkpoint blockade inhibition.